Lv11
35 积分 2021-08-29 加入
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study
4小时前
已完结
Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis
4小时前
已完结
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
17天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
4个月前
已完结
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
4个月前
已完结
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
5个月前
已完结
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
5个月前
已完结
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
5个月前
已完结
皖公网安备34019202002308
